Article Information
History
- December 4, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Manuela Di Fusco1,*,
- Diana Mendes2,
- Lotte Steuten3,
- David E Bloom4,
- Michael Drummond5,
- Katharina Hauck6,
- Jonathan Pearson-Stuttard7,8,
- Rachel Power9,
- David Salisbury10,
- Adrian Towse3,
- Julie Roiz11,
- Gabor Szabo12,
- Jingyan Yang1,13 and
- Kinga Marczell12
- 1Health Economics and Outcomes Research, Pfizer Inc, New York, USA
- 2Health & Value, Pfizer Ltd, Tadworth, UK
- 3Office of Health Economics, London SW1E 6QT, UK
- 4Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, USA
- 5Centre for Health Economics, Alcuin A Block, University of York, Heslington, York YO10 5DD, UK
- 6Department of Infectious Disease Epidemiology, Faculty of Medicine, School of Public Health, Imperial College London, London, UK
- 7Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
- 8Health Analytics, Lane Clark & Peacock, London, UK
- 9The Patients Association, PO Box 935, Harrow, Middlesex, HA1 3YJ, UK
- 10Programme for Global Health, Royal Institute of International Affairs, Chatham House, London, UK
- 11Evidence, Value and Access by PPD, Evidera, London, UK
- 12Evidence, Value and Access by PPD, Evidera, Budapest, Hungary
- 13Institute for Social and Economic Research and Policy, Graduate School of Arts and Science, Columbia University, New York, USA
- ↵*Correspondence: manuela.difusco{at}pfizer.com
Posted December 04, 2022.
The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as A Case Study
